Arrowhead Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Arrowhead Pharmaceuticals reports its first commercial launch of REDEMPLO for FCS, significant milestone payments from Sarepta and Novartis, and continued pipeline advancement in its latest 10-K filing.
NASDAQ
Arrowhead Pharmaceuticals filed an amendment to its annual report, providing detailed information on corporate governance, executive compensation, and director changes, alongside significant business and financial updates.
NASDAQ
Arrowhead Pharmaceuticals' 2024 annual report details a year of significant pipeline advancements, strategic collaborations, and financial activities, including a substantial net loss and a major financing agreement.